Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series.

Montanelli G, Beretta L, Santaniello A, Scorza R.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):135-9. Epub 2012 Dec 13.

PMID:
23295023
3.

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.

DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ.

Arthritis Rheum. 2002 Nov;46(11):2983-9.

4.

Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients.

Teixeira L, Mouthon L, Mahr A, Berezné A, Agard C, Mehrenberger M, Noël LH, Trolliet P, Frances C, Cabane J, Guillevin L; Group Français de Recherche sur le Sclérodermie (GFRS).

Ann Rheum Dis. 2008 Jan;67(1):110-6. Epub 2007 Jun 8.

PMID:
17557890
5.

[Scleroderma renal crisis].

Teixeira L, Servettaz A, Mehrenberger M, Noël LH, Guillevin L, Mouthon L.

Presse Med. 2006 Dec;35(12 Pt 2):1966-74. Review. French.

PMID:
17159723
6.

Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls.

Guillevin L, Bérezné A, Seror R, Teixeira L, Pourrat J, Mahr A, Hachulla E, Agard C, Cabane J, Vanhille P, Harle JR, Deleveaux I, Mouthon L.

Rheumatology (Oxford). 2012 Mar;51(3):460-7. doi: 10.1093/rheumatology/ker271. Epub 2011 Nov 15.

PMID:
22087012
7.

The scleroderma kidney: progress in risk factors, therapy, and prevention.

Bussone G, Bérezné A, Pestre V, Guillevin L, Mouthon L.

Curr Rheumatol Rep. 2011 Feb;13(1):37-43. doi: 10.1007/s11926-010-0145-7. Review.

PMID:
21061100
8.

Renal complications and scleroderma renal crisis.

Denton CP, Lapadula G, Mouthon L, Müller-Ladner U.

Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii32-5. doi: 10.1093/rheumatology/ken483. Review.

PMID:
19487221
9.

Serologic profile and mortality rates of scleroderma renal crisis in Italy.

Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, Del Papa N, Franceschini F, Guiducci S, Morozzi G, Ruffatti A, Ferri C, Giacomelli R, Matucci-Cerinic M, Valentini G, Montecucco C.

J Rheumatol. 2009 Jul;36(7):1464-9. doi: 10.3899/jrheum.080806. Epub 2009 Jun 1.

PMID:
19487262
10.

Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients.

Moinzadeh P, Riemekasten G, Siegert E, Fierlbeck G, Henes J, Blank N, Melchers I, Mueller-Ladner U, Frerix M, Kreuter A, Tigges C, Lahner N, Susok L, Guenther C, Zeidler G, Pfeiffer C, Worm M, Karrer S, Aberer E, Bretterklieber A, Genth E, Simon JC, Distler JH, Hein R, Schneider M, Seitz CS, Herink C, Steinbrink K, Sárdy M, Varga R, Mensing H, Mensing C, Lehmann P, Neeck G, Fiehn C, Weber M, Goebeler M, Burkhardt H, Buslau M, Ahmadi-Simab K, Himsel A, Juche A, Koetter I, Kuhn A, Sticherling M, Hellmich M, Kuhr K, Krieg T, Ehrchen J, Sunderkoetter C, Hunzelmann N; German Network for Systemic Scleroderma.

J Rheumatol. 2016 Jan;43(1):66-74. doi: 10.3899/jrheum.150382. Epub 2015 Nov 15.

11.

Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor.

Hesselstrand R, Scheja A, Wuttge DM.

Scand J Rheumatol. 2012 Feb;41(1):39-43. doi: 10.3109/03009742.2011.610032. Epub 2011 Nov 1.

PMID:
22044051
12.

Risk factors and outcome of Thai patients with scleroderma renal crisis: a disease duration-matched case control study.

Wangkaew S, Lertthanaphok S, Puntana S, Noppakun K.

Int J Rheum Dis. 2017 Oct;20(10):1562-1571. doi: 10.1111/1756-185X.13145. Epub 2017 Jul 27.

PMID:
28752678
13.

Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts.

Walker KM, Pope J; participating members of the Scleroderma Clinical Trials Consortium (SCTC); Canadian Scleroderma Research Group (CSRG).

Semin Arthritis Rheum. 2012 Aug;42(1):42-55. doi: 10.1016/j.semarthrit.2012.01.003. Epub 2012 Mar 29.

PMID:
22464314
14.

Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.

Bettoni L, Geri A, Airò P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R.

Clin Rheumatol. 2002 Jun;21(3):244-50.

PMID:
12111631
15.

Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis.

Li G, Adachi JD, Cheng J, Thabane L, Hudson M, Fritzler MJ, Lorenzi S, Baron M, Larché M; Canadian Scleroderma Research Group.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):56-60. Epub 2017 Jan 31.

PMID:
28229818
16.

Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.

Yamada H, Suga N, Maeda K, Kimura Y, Miura N, Futenma A, Imai H.

Arzneimittelforschung. 2010;60(2):64-70. doi: 10.1055/s-0031-1296250.

PMID:
20329653
17.

Corticosteroids and the risk of scleroderma renal crisis: a systematic review.

Trang G, Steele R, Baron M, Hudson M.

Rheumatol Int. 2012 Mar;32(3):645-53. doi: 10.1007/s00296-010-1697-6. Epub 2010 Dec 4. Review.

PMID:
21132302
18.

Scleroderma renal crisis: a rare but severe complication of systemic sclerosis.

Mouthon L, Bérezné A, Bussone G, Noël LH, Villiger PM, Guillevin L.

Clin Rev Allergy Immunol. 2011 Apr;40(2):84-91. doi: 10.1007/s12016-009-8191-5. Review.

PMID:
20012923
19.

Arterial stiffness is increased in systemic sclerosis: a cross-sectional comparison with matched controls.

Ngian GS, Sahhar J, Wicks IP, Van Doornum S.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-161-6. Epub 2014 Aug 15.

PMID:
25152081
20.

Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment.

Walker JG, Ahern MJ, Smith MD, Coleman M, Pile K, Rischmueller M, Cleland L, Roberts-Thomson PJ.

Intern Med J. 2003 May-Jun;33(5-6):216-20.

PMID:
12752889

Supplemental Content

Support Center